Potenciais interações medicamentosas responsáveis por internações hospitalares
Carregando...
Data
2013-04-08
Autores
Varallo, Fabiana Rossi [UNESP]
Costa, Marilia Amaral [UNESP]
Mastroianni, Patricia de Carvalho [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
As interações medicamentosas (IM) são consideradas um problema de saúde pública, pois podem causar resultados negativos à saúde dos usuários de medicamentos. Portanto o referido trabalho teve como objetivos: estimar a prevalência de internações hospitalares relacionadas a Potenciais IM (PIM); identificar os sinais e sintomas, e os fatores de risco para a hospitalização relacionados à PIM. Metodologia: Realizou-se estudo transversal na clínica geral de um hospital privado do interior de São Paulo (Brasil), em maio de 2006, com pacientes acima de 18 anos, com tempo de hospitalização superior a 24horas, sendo os mesmos entrevistados sobre os sintomas/motivos de internação e os medicamentos que haviam utilizado previamente à hospitalização. Calculou-se Odds-ratiopara identificar fatores de risco, sendo encontrado os seguintes resultados: 168 pacientes utilizando mais de um medicamento, dos quais 57 apresentaram PIM, sendo que em 17(10,1%), os sinais e sintomas da PIM possivelmente foram a causa da hospitalização. A maioria das manifestações clínicas das PIM foram sintomas cardiovasculares (44,3%), gastrintestinais (17,2%) e musculoesqueléticos (13,8%) e 10% das PIM foram consideradas potencialmente perigosas. Não foram detectados fatores de risco relacionados ao gênero, idade, uso de medicamentos de estreita faixa terapêutica para hospitalização por PIM. A polimedicação foi fator de risco para ocorrência de PIM (p < 0,0001) opostamente ao aumento da idade que revelou ser um fator de proteção (p=0,02). Conclusão: Se faz necessário seguimento farmacoterapêutico de pacientes que utilizam fármacos de estreita faixa terapêutica, pois estas substâncias estão frequentemente envolvidas em IM perigosas. Palavras-chave: Problema relacionado ao medicamento. Resultado negativo associado ao medicamento. Erros de medicação. Interações de medicamentos.
Potential drug interactions responsible for hospital admissions Drug-drug interactions (DDI) are considered a public health problem, since they may be the cause of negative outcomes for drug users. Research objectives: 1) estimate the prevalence of hospital admissions arising from potential DDI; 2) identify the signs and symptoms of, as well as risk factors for hospitalization related to, potential DDI. A cross-sectional study was performed in the general clinic of a private hospital in upstate São Paulo, in May 2006, focusing on patients over 18 years old, hospitalized for more than 24 hours, who were interviewed about their symptoms, reasons for hospitalization and the drugs taken prior to hospitalization. The odds ratio was calculated in order to identify risk factors. Results: 168 patients had taken more than one drug, of whom 57 showed potential DDI and, in 17 (10.1%), the signs and symptoms of DDI were probably the reason for hospitalization. The most frequent clinical manifestations of potential DDI were disorders in the cardiovascular (44.3%), digestive (17.2%) and musculoskeletal (13.8%) systems and 10% of the DDI identified were considered potentially hazardous. Risk factors for DDI-motivated hospitalization related to gender, age or the use of drugs with a narrow therapeutic range were not detected. Polypharmacy (p < 0.0001) was a determining factor for DDI; conversely, old age was a protection factor (p=0.02). Conclusion: pharmacotherapeutic follow-up of patients who use drugs with a narrow therapeutic range is essential, since these drugs are often involved in hazardous DDI. Pharmacotherapeutic follow-up is also recommended for polymedicated patients, to prevent hospitalization arising from avoidable DDI. Keywords: Drug-related problem. Negative outcome associated with medicines. Medication errors. Drug-drug interaction.
Potential drug interactions responsible for hospital admissions Drug-drug interactions (DDI) are considered a public health problem, since they may be the cause of negative outcomes for drug users. Research objectives: 1) estimate the prevalence of hospital admissions arising from potential DDI; 2) identify the signs and symptoms of, as well as risk factors for hospitalization related to, potential DDI. A cross-sectional study was performed in the general clinic of a private hospital in upstate São Paulo, in May 2006, focusing on patients over 18 years old, hospitalized for more than 24 hours, who were interviewed about their symptoms, reasons for hospitalization and the drugs taken prior to hospitalization. The odds ratio was calculated in order to identify risk factors. Results: 168 patients had taken more than one drug, of whom 57 showed potential DDI and, in 17 (10.1%), the signs and symptoms of DDI were probably the reason for hospitalization. The most frequent clinical manifestations of potential DDI were disorders in the cardiovascular (44.3%), digestive (17.2%) and musculoskeletal (13.8%) systems and 10% of the DDI identified were considered potentially hazardous. Risk factors for DDI-motivated hospitalization related to gender, age or the use of drugs with a narrow therapeutic range were not detected. Polypharmacy (p < 0.0001) was a determining factor for DDI; conversely, old age was a protection factor (p=0.02). Conclusion: pharmacotherapeutic follow-up of patients who use drugs with a narrow therapeutic range is essential, since these drugs are often involved in hazardous DDI. Pharmacotherapeutic follow-up is also recommended for polymedicated patients, to prevent hospitalization arising from avoidable DDI. Keywords: Drug-related problem. Negative outcome associated with medicines. Medication errors. Drug-drug interaction.
Descrição
Palavras-chave
Interação Medicamentosa, problema relacionado a medicamento, resultado negativo a medicamento, erros de medicação, interações de medicamentos, internação., Farmacoterapia, Farmacologia
Como citar
Revista de Ciências Farmacêuticas Básica e Aplicada, v. 34, n. 1, 2013, p. 79-85.